S. boulardii

Phase 3Small molecule

MMuhammad Aamir Latif

S. boulardii is one of 41 small molecule programs targeting Acute Diarrhea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute DiarrheaActive, not recruiting

GrowthActive, not recruiting

Acute DiarrheaPreclinical

Active, not recruiting

GrowthPhase 3

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

S. boulardii

MMuhammad Aamir Latif

Phase 3

1 3

Lovenox

Sanofi

Preclinical

2 4

Lenvima

Eisai

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Somavaratan

Herceptin

4 8

Glucophage

EMD Serono

Preclinical

2 9

Neupogen

EEastern Cooperative Oncology Group

Preclinical

1 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants

Completed·LLingfen Xu, MD·Phase 3·NCT02310425·125 enrolled

Acute Diarrhea1 trial

Zinc Plus Saccharomyces Boulardii Versus Zinc Alone in the Treatment of Acute Diarrhea

Completed·MMuhammad Aamir Latif·N/A·NCT07168304·276 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for S. boulardii. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S. boulardii compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S. boulardii. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Muhammad Aamir Latif company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMuhammad Aamir Latif

S. boulardii

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

Acute Diarrhea1 trial

References

Drug Info

Quick Facts

Related News